Brentuximab vedotin is an agent used for Hodgkin’s lymphoma (HL) CD30+, and it acts by secreting conjugated microtubule-disrupting agent monomethyl auristatin E (MMAE) against CD30 cancer cells. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.